Results 61 to 70 of about 28,560,894 (288)

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?

Journal of Diabetes Research, 2017
Background. The incretin effect is impaired in patients with type 2 diabetes. Aim. To assess the relation between the incretin hormone GLP-1 and the prediabetic subtypes: impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and the combined ...
Matthias Ploug Larsen, Signe Sørensen Torekov   +1 more
doaj   +1 more source

Sustainable Hydrogel‐Forming Microneedle‐Reservoir Patches for Transdermal Delivery of Hydrophilic Macromolecules: Biopolymers, Green Manufacturing and Translation

Advanced Science, EarlyView.
Hydrogel‐forming microneedle (HFMN)‐reservoir patches provide a modular route for controlled transdermal delivery of hydrophilic biomacromolecules. The platform integrates skin‐barrier penetration, sustainable biopolymers, scalable green manufacturing, hydration‐driven transport, model‐cargo validation, and translational quality requirements.
Siddharth Mohanty, Mehmet Onur Aydogdu, Sijia Kang, Xinbo Li, Mohan Edirisinghe   +4 more
wiley   +1 more source

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Journal of Pharmaceutical Policy and Practice
Background High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot
Michael J. DiStefano, Mouna Dardouri, Gina D. Moore, Joseph J. Saseen, Kavita V. Nair   +4 more
doaj   +1 more source

Reframing the Gut–Brain Axis: The Gut Wall as a Neural Immune Interface in Multiple Sclerosis and Autoimmune Neurological Diseases

Annals of Neurology, EarlyView.
Gut wall physiology in multiple sclerosis (MS) and autoimmune neurologic diseases remains underexplored but may span gut barrier dysfunction, enteric glial targeting, mucosal immune dysregulation, and autoimmune targets within the enteric nervous system (ENS).
Federico Montini, Sean J. Pittock, Laura Cacciaguerra, Howard L. Weiner, Luke A. Schwerdtfeger   +4 more
wiley   +1 more source

A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction

Communications Medicine
Background Heart damage caused by cancer treatment can lead to heart failure, hospital admission, and death. Medications known as glucagon-like peptide-1 receptor agonists are widely used to treat type 2 diabetes with cardioprotective potentials. Whether
Jheng-Yan Wu, Yu-Min Lin, Mei-Chuan Lee, Chung-Han Ho, Pei Yu Jhou, Wei-Ting Chang   +5 more
doaj   +1 more source

Continuous glucose monitoring guides glucagon-like peptide 1-based therapy use and optimization in people with type 2 diabetes

Journal of Family Medicine and Primary Care
Type 2 diabetes (T2D) is a large and growing epidemic. Importantly, new technologies and pharmaceutical options are improving the management of T2D. Continuous glucose monitoring (CGM) systems have advanced glucose-sensing technology, which has made it ...
Rita Parsiani, Thomas Grace, Courtney R. Green, Jessica R. Castle, Leah M. Wilson   +4 more
doaj   +1 more source

Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]

, 2014
Adam M.
Deane, A., Horowitz, M.
core   +1 more source

Characterisation and validation of drug transport and GLP-1R function in primary porcine proximal tubular cells [PDF]

, 2006
Overview kidney: Kidney is, beside the liver, one of the most important organs for the elimination of waste products, toxins, drugs and their metabolites. Due to the anatomy of the kidney, ultra filtrate leaving the glomerulus passes first the proximal
Schlatter, Philipp
core   +1 more source

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2 [PDF]

Current Opinion in Lipidology, 2018
Purpose of review The intestine is highly efficient at absorbing and packaging dietary lipids onto the structural protein apoB48 for distribution throughout the body. Here, we summarize recent advances into understanding the physiological and pharmacological actions of the proglucagon-derived peptides: glucagon like peptide 1 ...
openaire   +2 more sources